Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Pfizer expects to sufficiently de-lever its balance sheet ... the potential to return capital to shareholders through share repurchases. Fourth-quarter 2024 Comirnaty (1) revenues of $3.4 billion ...

although this was offset by a $2 billion decline in revenues from the company's Comirnaty COVID drug. Pfizer's growth is expected to accelerate, Edward Jones analyst John Boylan said in a note ...

(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Source: Pfizer.